Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150351460> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2150351460 endingPage "172" @default.
- W2150351460 startingPage "168" @default.
- W2150351460 abstract "Prostate inhibin peptide (PIP) is a follicle-stimulating hormone (FSH) regulating peptide produced by the prostate. The mechanism of its endocrine role in regulating prostate growth is believed to be androgen-independent but FSH-dependent. Previous studies using polyclonal antibody proposed PIP as a prostatic-specific marker in cancer diagnosis. However, the recently available monoclonal antibody has not yet been evaluated. Paraffin sections of 72 prostatectomy specimens for prostate cancer with or without hormonal blockage therapy and 10 nonneoplastic prostate tissues from autopsy were stained by using PIP monoclonal antibody (clone: 4A6A6) with the avidin-biotin complex method. PIP reactivity was semiquantitatively estimated in prostatic carcinoma (PCA), prostatic intraepithelial neoplasia (PIN), benign prostatic hyperplasia (BPH) and normal tissue in each case when ever present. Statistical analyses were performed accordingly. PIP expression is predominantly cytoplasmic. Urothelium, seminal vesicles, inflamed prostatic glands, basal cells, and squamous metaplasia were negative for PIP. Average percentage of cells expressing PIP was significantly decreased in PIN (40%) and PCA (14%) when compared with BPH (81%) and normal tissue (68%). There was no correlation of tumor PIP level with patient's age, tumor size, Gleason score, tumor stage, or the usage of preoperative hormonal blockage therapy. PIP monoclonal antibody should be used with caution as a prostate-specific marker in surgical pathology. The mechanism for this alteration and the effect of PIP on prostatic tumor growth, particularly in patients under a variety of hormonal therapies, needs further study." @default.
- W2150351460 created "2016-06-24" @default.
- W2150351460 creator A5017681321 @default.
- W2150351460 creator A5045548671 @default.
- W2150351460 creator A5062825050 @default.
- W2150351460 creator A5080639509 @default.
- W2150351460 creator A5087322911 @default.
- W2150351460 date "1999-02-01" @default.
- W2150351460 modified "2023-09-26" @default.
- W2150351460 title "Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: A study with monoclonal antibody" @default.
- W2150351460 cites W1976238420 @default.
- W2150351460 cites W2009979228 @default.
- W2150351460 cites W2013713901 @default.
- W2150351460 cites W2028373666 @default.
- W2150351460 cites W2042770436 @default.
- W2150351460 cites W2099113999 @default.
- W2150351460 cites W2100058173 @default.
- W2150351460 cites W2111987375 @default.
- W2150351460 cites W2397842152 @default.
- W2150351460 cites W2441155430 @default.
- W2150351460 cites W72011126 @default.
- W2150351460 doi "https://doi.org/10.1016/s0046-8177(99)90271-x" @default.
- W2150351460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10029444" @default.
- W2150351460 hasPublicationYear "1999" @default.
- W2150351460 type Work @default.
- W2150351460 sameAs 2150351460 @default.
- W2150351460 citedByCount "13" @default.
- W2150351460 countsByYear W21503514602012 @default.
- W2150351460 countsByYear W21503514602014 @default.
- W2150351460 countsByYear W21503514602015 @default.
- W2150351460 countsByYear W21503514602019 @default.
- W2150351460 countsByYear W21503514602020 @default.
- W2150351460 countsByYear W21503514602022 @default.
- W2150351460 crossrefType "journal-article" @default.
- W2150351460 hasAuthorship W2150351460A5017681321 @default.
- W2150351460 hasAuthorship W2150351460A5045548671 @default.
- W2150351460 hasAuthorship W2150351460A5062825050 @default.
- W2150351460 hasAuthorship W2150351460A5080639509 @default.
- W2150351460 hasAuthorship W2150351460A5087322911 @default.
- W2150351460 hasBestOaLocation W21503514601 @default.
- W2150351460 hasConcept C121608353 @default.
- W2150351460 hasConcept C126322002 @default.
- W2150351460 hasConcept C142724271 @default.
- W2150351460 hasConcept C159654299 @default.
- W2150351460 hasConcept C203014093 @default.
- W2150351460 hasConcept C2776235491 @default.
- W2150351460 hasConcept C2777562237 @default.
- W2150351460 hasConcept C2779534503 @default.
- W2150351460 hasConcept C2780192828 @default.
- W2150351460 hasConcept C542903549 @default.
- W2150351460 hasConcept C71924100 @default.
- W2150351460 hasConceptScore W2150351460C121608353 @default.
- W2150351460 hasConceptScore W2150351460C126322002 @default.
- W2150351460 hasConceptScore W2150351460C142724271 @default.
- W2150351460 hasConceptScore W2150351460C159654299 @default.
- W2150351460 hasConceptScore W2150351460C203014093 @default.
- W2150351460 hasConceptScore W2150351460C2776235491 @default.
- W2150351460 hasConceptScore W2150351460C2777562237 @default.
- W2150351460 hasConceptScore W2150351460C2779534503 @default.
- W2150351460 hasConceptScore W2150351460C2780192828 @default.
- W2150351460 hasConceptScore W2150351460C542903549 @default.
- W2150351460 hasConceptScore W2150351460C71924100 @default.
- W2150351460 hasIssue "2" @default.
- W2150351460 hasLocation W21503514601 @default.
- W2150351460 hasLocation W21503514602 @default.
- W2150351460 hasOpenAccess W2150351460 @default.
- W2150351460 hasPrimaryLocation W21503514601 @default.
- W2150351460 hasRelatedWork W1971531012 @default.
- W2150351460 hasRelatedWork W1980245127 @default.
- W2150351460 hasRelatedWork W2019340165 @default.
- W2150351460 hasRelatedWork W2028329711 @default.
- W2150351460 hasRelatedWork W2062676201 @default.
- W2150351460 hasRelatedWork W2352355015 @default.
- W2150351460 hasRelatedWork W2357527027 @default.
- W2150351460 hasRelatedWork W2386364393 @default.
- W2150351460 hasRelatedWork W2903166683 @default.
- W2150351460 hasRelatedWork W3014716101 @default.
- W2150351460 hasVolume "30" @default.
- W2150351460 isParatext "false" @default.
- W2150351460 isRetracted "false" @default.
- W2150351460 magId "2150351460" @default.
- W2150351460 workType "article" @default.